SEBELA IRELAND LTD — Patent Portfolio
1 drug with active patents · 6 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict The SEBELA IRELAND LTD portfolio is moderately vulnerable with a significant cliff year in 2028, where 1 drug loses exclusivity, including Sporanox.
Portfolio overview The SEBELA IRELAND LTD portfolio consists of a total of 2 drugs, with 1 of them having patents. The company has a total of 6 US patents, all of which are active, and no expired patents. The average vulnerability score of the patents is 55, indicating a moderate level of vulnerability. The patent estate is predominantly vulnerable, with 1 ironclad patent and 1 vulnerable patent.
Cliff calendar The SEBELA IRELAND LTD portfolio faces a significant cliff year in 2028, where 1 drug loses exclusivity, including Sporanox. This is the only year with a notable number of drugs losing exclusivity.
Most exposed drugs The top drug facing near-term loss of exclusivity is Sporanox, with an earliest active patent expiry date of 2028-10-03, an average vulnerability score of 55, and no annual revenue data available. This drug has 6 patents and is the only drug in the portfolio with a significant vulnerability score.
Biologic exclusivity There are no biologics in the SEBELA IRELAND LTD portfolio.
Strategic implications The total revenue at risk in the next 5 years is $0. The company should consider lifecycle moves such as subQ switches, label extensions, and combination filings to mitigate the impact of the loss of exclusivity of Sporanox in 2028.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Sporanox (itraconazole)
Cliff 2028 · 2y-
US8486456
Vuln 80
2028-10-03
This patent protects a solid dispersion product containing itraconazole and hydroxypropyl methylcellulose with improved bioavailability.
-
US10463740
Vuln 62
2033-06-21
This patent protects pharmaceutical compositions, including solid oral dosage forms, containing itraconazole for treating fungal infections.
-
US9713642
Vuln 62
2033-06-21
This patent protects pharmaceutical compositions containing itraconazole, including solid oral dosage forms, and methods of using them to treat fungal infections.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 3 patents
- Formulation 3 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track SEBELA IRELAND LTD's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export